CLAIMS

~~1. A use of a modulatory agent in the preparation of a medicament for preventing or treating a hepatocellular carcinoma negative for Hepatitis B virus/Hepatitis C virus infection (NBNC-HCC), wherein the modulatory agent controls a genetic alteration of CD36 gene and/or ABCG4 gene in a subject.~~

~~2. The use of claim 1, wherein the genetic alteration comprises *CD36* amplification.~~

~~3. The use of claim 1, wherein the genetic alteration comprises *ABCG4* deletion.~~

~~4. The use of claim 1, wherein the genetic alteration comprises *CD36* amplification and *ABCG4* deletion.~~

~~5.~~1. A use of a modulatory agent in the preparation of a medicament for preventing or treating a hepatocellular carcinoma negative for Hepatitis B virus/Hepatitis C virus infection (NBNC-HCC) in a subject, comprising a therapeutically effective amount of the modulatory agent for inhibiting CD36 protein expression or function ~~and/or promoting ABCG4 protein expression or function~~.

~~6.~~2. The use of claim 1~~5~~, wherein the modulatory agent is an agent to suppress *CD36* overexpression.

~~7.~~3. The use of claim 1~~5 or 6~~, wherein the modulatory agent blocks lipid uptake in the hepatocellular carcinoma cells.

~~8.~~4. The use of claim 1~~7~~, wherein the modulatory agent is an anti-CD36 antibody.

~~9. The use of claim 5, wherein the modulatory agent is an agent to induce *ABCG4* expression.~~

~~10. The use of claim 5 or 9, wherein the modulatory agent promotes cholesterol transport within the hepatocellular carcinoma cells.~~

~~11. The use of claim 10, wherein the modulatory agent is an ABCG4 protein~~.